These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 22178753)
1. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization. Dekeyne A; Brocco M; Loiseau F; Gobert A; Rivet JM; Di Cara B; Cremers TI; Flik G; Fone KC; Watson DJ; Papp M; Sharp T; Serres F; Cespuglio R; Olivier B; Chan JS; Lavielle G; Millan MJ J Pharmacol Exp Ther; 2012 Mar; 340(3):765-80. PubMed ID: 22178753 [TBL] [Abstract][Full Text] [Related]
2. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752 [TBL] [Abstract][Full Text] [Related]
3. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196 [TBL] [Abstract][Full Text] [Related]
4. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Dekeyne A; Mannoury la Cour C; Gobert A; Brocco M; Lejeune F; Serres F; Sharp T; Daszuta A; Soumier A; Papp M; Rivet JM; Flik G; Cremers TI; Muller O; Lavielle G; Millan MJ Psychopharmacology (Berl); 2008 Sep; 199(4):549-68. PubMed ID: 18523738 [TBL] [Abstract][Full Text] [Related]
5. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity. Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092 [TBL] [Abstract][Full Text] [Related]
6. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Brocco M; Dekeyne A; Papp M; Millan MJ Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388 [TBL] [Abstract][Full Text] [Related]
7. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis. Millan MJ; Gobert A; Roux S; Porsolt R; Meneses A; Carli M; Di Cara B; Jaffard R; Rivet JM; Lestage P; Mocaer E; Peglion JL; Dekeyne A J Pharmacol Exp Ther; 2004 Oct; 311(1):190-203. PubMed ID: 15146031 [TBL] [Abstract][Full Text] [Related]
8. On the mechanism of antidepressant-like action of berberine chloride. Kulkarni SK; Dhir A Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703 [TBL] [Abstract][Full Text] [Related]
9. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity. Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549 [TBL] [Abstract][Full Text] [Related]
10. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Millan MJ; Brocco M; Gobert A; Dekeyne A Psychopharmacology (Berl); 2005 Feb; 177(4):448-58. PubMed ID: 15289999 [TBL] [Abstract][Full Text] [Related]
11. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900 [TBL] [Abstract][Full Text] [Related]
12. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Deltheil T; Guiard BP; Cerdan J; David DJ; Tanaka KF; Repérant C; Guilloux JP; Coudoré F; Hen R; Gardier AM Neuropharmacology; 2008 Nov; 55(6):1006-14. PubMed ID: 18761360 [TBL] [Abstract][Full Text] [Related]
13. S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. Millan MJ; Lejeune F; Gobert A; Brocco M; Auclair A; Bosc C; Rivet JM; Lacoste JM; Cordi A; Dekeyne A J Pharmacol Exp Ther; 2000 Dec; 295(3):1206-22. PubMed ID: 11082458 [TBL] [Abstract][Full Text] [Related]
14. The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats. Millan MJ; Gobert A; Panayi F; Rivet JM; Dekeyne A; Brocco M; Ortuno JC; Di Cara B Int J Neuropsychopharmacol; 2008 Dec; 11(8):1105-22. PubMed ID: 18466669 [TBL] [Abstract][Full Text] [Related]
15. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs? Consoli D; Leggio GM; Mazzola C; Micale V; Drago F Eur J Pharmacol; 2007 Nov; 573(1-3):139-47. PubMed ID: 17669397 [TBL] [Abstract][Full Text] [Related]